Bayesian Capital Management LP Takes Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Bayesian Capital Management LP bought a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 32,500 shares of the life sciences company's stock, valued at approximately $737,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IART. Quadrant Capital Group LLC grew its position in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after buying an additional 1,371 shares in the last quarter. Sterling Capital Management LLC raised its holdings in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after acquiring an additional 2,800 shares during the period. Covestor Ltd boosted its stake in Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after purchasing an additional 2,071 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences in the fourth quarter worth $180,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Price Performance

Shares of NASDAQ IART traded down $0.64 during midday trading on Friday, reaching $12.25. The company's stock had a trading volume of 1,542,604 shares, compared to its average volume of 1,037,372. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a one year low of $11.60 and a one year high of $32.66. The company has a market cap of $951.97 million, a price-to-earnings ratio of -136.10, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. The company has a 50 day moving average price of $18.93 and a 200 day moving average price of $21.88.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The business had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.55 earnings per share. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IART. Truist Financial reduced their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. JPMorgan Chase & Co. lowered their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. JMP Securities lowered their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday. Finally, Wells Fargo & Company reduced their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.